Pediatric Drugs
Editor: R. McNab

Pediatric Drugs promotes the optimization and advancement of all aspects of pharmacotherapy for healthcare professionals interested in pediatric drug therapy (including vaccines). The program of reviews and original research articles provides healthcare decision makers with clinically applicable knowledge on issues relevant to drug therapy in all areas of neonatology and the care of children and adolescents, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of pediatric conditions; and the practical management of specific clinical situations.

Pediatric Drugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.

All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.

Impact Factor: 2.000 (2017), Journal Citation Reports®

On the homepage of Pediatric Drugs at springer.com you can

- Sign up for our Table of Contents Alerts
- Get to know the complete Editorial Board
- Find submission information